Analysts Set OPKO Health, Inc. (NASDAQ:OPK) Price Target at $2.28

OPKO Health, Inc. (NASDAQ:OPK) has been given an average rating of “Hold” by the seven research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $2.2833.

OPK has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a “hold” rating and set a $1.60 price objective (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. Wall Street Zen raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Barrington Research reissued an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Thursday, October 30th. Finally, JPMorgan Chase & Co. began coverage on OPKO Health in a research note on Thursday, November 20th. They issued a “neutral” rating for the company.

OPKO Health Stock Up 1.7%

Shares of NASDAQ:OPK opened at $1.20 on Friday. OPKO Health has a 1 year low of $1.11 and a 1 year high of $2.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.70 and a quick ratio of 3.32. The business’s 50-day moving average is $1.27 and its 200-day moving average is $1.36. The company has a market capitalization of $921.24 million, a price-to-earnings ratio of -4.80 and a beta of 1.47.

OPKO Health (NASDAQ:OPK) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. OPKO Health had a negative return on equity of 13.67% and a negative net margin of 28.10%.The business had revenue of $148.50 million during the quarter, compared to analysts’ expectations of $139.76 million. During the same quarter last year, the firm posted $0.01 earnings per share. The firm’s revenue was down 19.1% on a year-over-year basis. Equities research analysts predict that OPKO Health will post -0.25 earnings per share for the current year.

OPKO Health News Roundup

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Q4 EPS beat — OPKO reported GAAP EPS of ($0.04) versus consensus around ($0.07), showing better-than-expected per?share results for the quarter. Zacks: Q4 results
• Positive Sentiment: Large collaboration with Regeneron — OPKO’s ModeX platform entered a multispecific-antibody research partnership with Regeneron that includes an upfront payment, program milestones and potential royalties; the total collaboration value can exceed $1B if multiple programs succeed. This materially de-risks upside for investors if programs progress. Press release
• Positive Sentiment: Pipeline progress and partner programs — MDX2003 cleared for Phase 1 in Australia, MDX2004/MDX2001 updates were presented at major conferences, and Merck completed a Phase 1 EBV vaccine trial — all signals of clinical momentum. Earnings call transcript
• Positive Sentiment: Solid liquidity and buyback capacity — OPKO reported ~$369.1M in cash and equivalents and has repurchased ~$87.3M of stock with ~ $112.7M remaining authorization, supporting near-term capital flexibility. Press release
• Neutral Sentiment: Analyst stance — Recent consensus rating is “Hold” with median price targets below some upside scenarios; that keeps expectations tempered. Analyst note
• Negative Sentiment: Revenue decline and asset sales — Consolidated Q4 revenue fell to $148.5M (down ~19% YoY), primarily due to sale of BioReference assets, signaling near-term top-line pressure. Press release
• Negative Sentiment: Guidance below Street — 2026 revenue guidance of $530M–$560M and Q1 revenue guidance of $125M–$140M were issued; the full?year midpoint is below some consensus estimates, which may cap multiple expansion. Quiver / release summary
• Negative Sentiment: Wider losses — OPKO reported a Q4 net loss of $31.3M and larger operating losses versus prior year, reflecting higher R&D spend and transition costs that could pressure near-term earnings. Quiver / release summary

Hedge Funds Weigh In On OPKO Health

A number of institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in OPKO Health in the 4th quarter valued at $145,000. EP Wealth Advisors LLC bought a new position in shares of OPKO Health in the fourth quarter valued at $37,000. XTX Topco Ltd acquired a new position in shares of OPKO Health during the fourth quarter valued at about $432,000. Zacks Investment Management acquired a new position in shares of OPKO Health during the fourth quarter valued at about $27,000. Finally, Quadrature Capital Ltd bought a new stake in shares of OPKO Health during the fourth quarter worth about $116,000. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.